Retinal Conditions

Neovascular (Wet) AMD

Age-related macular degeneration (AMD) is a condition that affects the central retina (macula), which is most important for reading vision and daily tasks. Neovascular (also called “wet” because of the presence of abnormal fluid or blood) AMD is an advanced form of the disease and can cause rapid and severe loss of central vision in one or both eyes. A diagnosis of wet AMD used to mean unavoidable loss of vision, but current treatments allow retina specialists to control the disease in the vast majority of cases.

What causes Wet AMD?
The onset of age-related macular degeneration is determined largely by genetics, environmental factors and age. Only a small fraction of individuals with AMD go on to develop the advanced wet form, and this progression cannot currently be accurately predicted by genetics. Smoking greatly increases the risk of developing wet AMD.

In the wet form of AMD, abnormal blood vessels grow under the retina. These blood vessels can leak or break, resulting in blood or fluid collections. If this occurs behind the central retina, vision can drop dramatically. If treatment is delayed, blood or fluid can be toxic to the retina, resulting in permanent damage which cannot be fully treated.

How is Wet AMD diagnosed?

Because several different diseases can produce blood or fluid in the central retina, your
retina specialist will usually order tests to confirm the diagnosis of wet AMD and also
document a starting point for treatment in order to measure progress over time.
Optical coherence tomography (OCT) is a fast, non-invasive scan of the retina which
measures and locates fluid in and behind the retina. Fundus photography is the use of high
resolution photographs to document the tissue appearance. Fluorescein angiography (FA)
identifies the source of leakage of fluid under and within the retina with a series of timed
photographs taken after intravenous injection of fluorescein dye.
Your BARA doctor will use these diagnostic tests to monitor the response of disease to
treatment over time. OCT is used to monitor changes most frequently, while the other tests
are repeated less often.

 

Treatment of wet AMD

The primary treatment for wet AMD is injection of medication into the back part of the eye,
known as the vitreous. The leakage of blood and fluid in wet AMD is caused by a hormone
called VEGF (vascular endothelial growth factor). The medicines injected into the eye block
this hormone (anti-VEGF medicines). There are four medicines currently injected into the
eye as treatment for wet AMD:

AVASTIN. Avastin (bevacizumab) has been used for treatment of wet AMD since 2005, and
millions of injections have been given since then. Avastin was initially developed for intravenous
use in patients with colon cancer and was FDA-approved for that purpose, before retina
specialists began using it off-label for treatment of retinal disease. A large randomized clinical
trial (the CATT Study) conducted by the National Institutes of Health (NIH) directly compared
Lucentis and Avastin, and in 2012, the study showed that over two years of treatment, Avastin
was approximately equivalent to Lucentis in efficacy.


LUCENTIS. Lucentis (ranibizumab) was developed for use in wet AMD and was FDA-approved
for this purpose in 2006. The medicine costs approximately $2,000 per injection. At a molecular
level, Lucentis is very similar to Avastin. Lucentis has been studied extensively in large
randomized clinical trials, providing the highest quality evidence for its effectiveness and safety.
 

EYLEA. Eylea (aflibercept) was FDA-approved for treatment of wet AMD in 2011. This medicine
costs almost the same as Lucentis; while it is also an anti-VEGF class medication, its binding to
the target molecule works differently. A large randomized study showed that Eylea is effective
when compared to Lucentis and may be used at less frequent treatment intervals in some
patients.
 

BEOVU. Beovu (brolucizumab) was FDA approved for treatment of wet AMD in 2019 after clinical
trials demonstrated non-inferiority to Eylea over a year of treatment. In 2020, the FDA approved
an update to the label for Beovu to include safety information related to retinal vasculitis and
retinal vascular occlusion as possible complications of treatment with this medication.

Anti-VEGF injections do not cure wet AMD. The injections reduce bleeding and fluid leakage behind the retina but ongoing injections are usually needed to control the disease regardless of which medication is injected. Your retina specialist will talk to you about what to expect over the course of treatment.

 

Photodynamic therapy (PDT) is an additional treatment sometimes used for treatment of wet AMD. PDT by itself is not as effective as anti-VEGF medicines, but in selected cases, PDT combined with anti-VEGF therapy can provide good results and reduce the number of injections needed to control the disease. PDT consists of intravenous injection of a medicine called Verteporfin, followed by a laser treatment that activates the drug in the area of leaking blood vessels behind the retina.
 

Bay Area Retina Associates has eight offices around the East Bay region of the San Francisco Bay Area.
For billing and insurance questions, please call  (925) 522-8858 or fax to (925) 938-3697. For appointments, please contact the nearest BARA office directly.